Senescence-associated reprogramming promotes cancer stemness

Maja Milanovic, Dorothy Ngo-Yin Fan, Dimitri Belenki, +20

Nature

Tumor BiologyLineage PlasticityStem Cell ResearchCellular SenescenceMedicine +2

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Lynn Quek, Muriel D. David, Alison Kennedy, +22

Nature Medicine

Hematological MalignancyClonal HeterogeneityMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia +9

Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage

Lynn Quek, Georg Otto, Catherine Garnett, +30

The Journal of Experimental Medicine

Cell Surface Cd34Mixed-phenotype Acute LeukemiaLsc Differentiation ArrestStem Cell BiologyTumor Biology +16

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome

Maurice Labuhn, Kelly Perkins, Sören Matzk, +31

Cancer Cell

Down SyndromeMyeloid PreleukemiaTransformed Myeloid LeukemiaHematological MalignancyMixed-phenotype Acute Leukemia +6

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Charles Craddock, Aimee E. Houlton, Lynn Quek, +18

Clinical Cancer Research

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging

Niels Asger Jakobsen, Sven Turkalj, Andy G.X. Zeng, +27

Cell stem cell

Adult Stem CellImmunologyMyeloid NeoplasiaInflammationStem Cell Mobilization +16

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia

Lynn Quek, Paul Ferguson, Marlen Metzner, +16

Blood Advances

High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity

M. Decatris, P M Wilkinson, Richard Welch, +3

Annals of Oncology

Effective First-line TherapyHematological MalignancyHealth SciencesMedicineHematology +9

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Sylvie Freeman, Abin Thomas, Ian Thomas, +19

Blood

Gemtuzumab OzogamicinMixed-phenotype Acute LeukemiaPathologyPharmacotherapyMyeloid Neoplasia +14

A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation

Damien Roos‐Weil, Camille Decaudin, Marine Armand, +33

Cancer Discovery